He emphasized that India has made significant progress in generic drugs and medications not covered by patents in markets such as the United States and the United Kingdom, highlighting considerable potential for further growth of Indian pharmaceuticals in Europe.
He expressed pride in the fact that 60% of COVID-19 vaccines in the UK are sourced from Wockhardt, adding that one of the company’s promising antibiotics is advancing quickly and will soon be prepared to enter major Western markets, including the US.
Also Read: Wockhardt swings to profit in Q3, reports multifold growth in EBITDA
Emphasizing the importance of effectively communicating India’s achievements in the area of Intellectual Property Rights (IPR) to the Western world, he stated that India’s commitment to IPR is complemented by its effort to balance it with public welfare.
He mentioned that the company is in advanced discussions for potential partnerships as part of its expansion strategy and urged Indian policymakers to eliminate obstacles to create a conducive business environment, citing the 6.5% growth in India as indicative of vast opportunities in the current global landscape.
